Guangdong VTR Bio-Tech Co Ltd
SZSE:300381
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its Industry Average (40.5), the stock would be worth ¥-26.15 (478% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -10.7 | ¥6.92 |
0%
|
| Industry Average | 40.5 | ¥-26.15 |
-478%
|
| Country Average | 28.8 | ¥-18.58 |
-368%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Guangdong VTR Bio-Tech Co Ltd
SZSE:300381
|
3.4B CNY | -10.7 | 523 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -211 184.9 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
365.2B USD | 23.7 | 87.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
177.8B USD | 27 | 23 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
163.4B USD | 18.5 | 19.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -531.1 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.7B USD | 31.2 | 27.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.1B USD | 13.9 | 16.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 142.2 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -64.3 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60.2B AUD | 20.6 | 29.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 14.5 |
| Median | 28.8 |
| 70th Percentile | 57 |
| Max | 307 555.7 |
Other Multiples
Guangdong VTR Bio-Tech Co Ltd
Glance View
Guangdong VTR Bio-Tech Co., Ltd. is engaged in the research & development, production, sales and service of biological pharmacy, bio-enzyme preparation, microbe preparation, functional additives and green bio-manufacturing engineering. The company is headquartered in Zhuhai, Guangdong and currently employs 2,807 full-time employees. The company went IPO on 2014-01-28. The firm principally engages in the manufacture and distribution of feedstuff additives, additive pre-mixed feedstuffs, veterinary powders and granules. The Company’s products include enzyme preparations for feedstuffs, including composite enzyme for feedstuffs, phytase for feedstuffs and xylanase for feedstuffs, among others; bio-energy enzyme preparations; spinning enzyme products; food enzyme products; paper making enzyme products; other feedstuff additives, including antioxidants, acidifiers, attractants and fructo oligo saccharides feedstuff additives, as well as veterinary Chinese medicines.
